Impact of immunotherapy on outcomes of cutaneous melanoma and concurrent brain metastasis: a surveillance, epidemiology, and end results analysis of 2010–2020
Authors:
- 5 December 2025
- journal article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 144, 111781
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2021
- Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapiesCancer, 2021
- Predictive value of a nomogram for melanomas with brain metastases at initial diagnosisCancer Medicine, 2019
- Sex Differences in MelanomaCurrent Epidemiology Reports, 2019
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysisThe Lancet Oncology, 2018
- Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapiesCancer, 2017
- Metastatic melanoma: prognostic factors and survival in patients with brain metastasesJournal of Neuro-Oncology, 2017
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialThe Lancet Oncology, 2017
- Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastasesJournal of Neuro-Oncology, 2016
- Predictors of Survival, Neurologic Death, Local Failure, and Distant Failure After Gamma Knife Radiosurgery for Melanoma Brain MetastasesWorld Neurosurgery, 2014